Stocks
Allogene Therapeutics (ALLO) EBITDA US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA, bln rub | ? | -184.9 | -258.2 | -255.8 | -335.4 | -287.0 | -270.7 | ||
| Changes by years, y/y, % | -11% | +40% | -1% | +31% | -14% | +6.6% | |||
Allogene Therapeutics. EBITDA US GAAP, bln rub
Allogene Therapeutics. EBITDA US GAAP, changes, %
Allogene Therapeutics. EBITDA US GAAP, sum by quarters, bln rub
Allogene Therapeutics (ALLO) EBITDA US GAAP (quarter values) |
||||||||
| 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
| EBITDA, bln rub | ? | -99.1 | -76.9 | -59.4 | -68.5 | -65.9 | -270.7 | |
| Changes by years, y/y, % | +30% | +5% | -24% | -29% | -33% | |||
| Changes by quarters, q/q, % | +3% | -22% | -23% | +15% | -4% | |||
